Serine

Serine

SCHEMBL21988620

C=C(C)C(=O)O.NC(CO)C(=O)O

nearest known ligand 0.50

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GRIK1 P39086 9/20 0.50
▸ GRIK2 Q13002 6/20 0.50
▸ GRM1 Q13255 2/20 0.50
▸ GRM2 Q14416 2/20 0.50
▸ SLC1A1 P43005 4/20 0.45
▸ TGFBR1 P36897 1/20 0.44
▸ SLC7A5 Q01650 2/20 0.43
▸ PTGS1 P23219 2/20 0.41
▸ SLC7A11 Q9UPY5 1/20 0.41
▸ GRIA4 P48058 4/20 0.39
▸ GRIK3 Q13003 4/20 0.39
▸ GRIK5 Q16478 4/20 0.39
▸ SLC1A3 P43003 4/20 0.39
▸ SLC1A2 P43004 4/20 0.39
▸ GRIA2 P42262 3/20 0.38
▸ GRIA1 P42261 2/20 0.38
▸ GRM8 O00222 1/20 0.38
▸ GRM6 O15303 1/20 0.38
▸ GRIN2D O15399 1/20 0.38
▸ GRIN3B O60391 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Serine SCHEMBL4946751 1.00 GRIK1 (0.50) GRIK1GRIK2GRM1GRM2SLC1A1
Serine SCHEMBL7051757 0.91 GRIK1 (0.48) GRIK1GRIK2GRM1GRM2SLC1A1
Serine SCHEMBL4562562 0.89 TDP1 (0.52) GRIK1GRIK2GRM1GRM2SLC1A1
Serine SCHEMBL28752291 0.89 TDP1 (0.52) GRIK1GRIK2GRM1GRM2SLC1A1
Serine SCHEMBL5338147 0.86 GRIK1 (0.50) GRIK1GRIK2GRM1GRM2SLC1A1
Serine SCHEMBL850904 0.86 GRIK1 (0.50) GRIK1GRIK2GRM1GRM2SLC1A1
Serine SCHEMBL2509471 0.85 SLC1A1 (0.52) GRIK1GRIK2GRM1GRM2SLC1A1
Serine SCHEMBL2166438 0.85 SLC1A1 (0.52) GRIK1GRIK2GRM1GRM2SLC1A1
Serine SCHEMBL2166436 0.85 SLC1A1 (0.52) GRIK1GRIK2GRM1GRM2SLC1A1
Serine SCHEMBL25336671 0.84 GRIK1 (0.52) GRIK1GRIK2GRM1GRM2SLC1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250205360-A1 FUNCTIONALIZED CORE-SHELL NANOGEL SCAVENGER FOR IMMUNE MODULATION THERAPY UNIV NEW YORK STATE RES FOUND (US) 2025-06-26 — — US claimed
CN-118440526-A Zwitterionic hydrophilic coating and preparation method and application thereof 广东省科学院生物与医学工程研究所 2024-08-06 — — CN claimed
US-11912894-B2 Antimicrobial and antifouling conformal hydrogel coatings CORNELL UNIVERSITY (US) 2024-02-27 — — US claimed
CN-115845135-B Anti-fouling wear-resistant lubricating coating similar to articular cartilage and preparation method thereof 中山大学 2024-02-23 — — CN claimed
WO-2023192494-A2 FUNCTIONALIZED CORE-SHELL NANOGEL SCAVENGER FOR IMMUNE MODULATION THERAPY THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) 2023-10-05 — — WO claimed
WO-2023076220-A1 CONJUGATES HAVING ANTIFOULING NANOPARTICLES AND METHODS OF USE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2023-05-04 — — WO claimed
CN-115845135-A Articular cartilage-like anti-pollution wear-resistant lubricating coating and preparation method thereof 中山大学 2023-03-28 — — CN claimed
US-20200172741-A1 ANTIMICROBIAL AND ANTIFOULING CONFORMAL HYDROGEL COATINGS CORNELL UNIVERSITY 2020-06-04 — — US claimed
CN-106334463-B A kind of anti-pollution polyvinylidene fluoride hollow-fibre membrane and preparation method thereof 东华大学 2019-02-01 — — CN claimed
CN-106334463-A Anti-pollution polyvinylidene fluoride hollow-fiber membrane and preparation method thereof 东华大学 2017-01-18 — — CN claimed
US-12577278-B2 KRAS G12V mutant binds to JAK1, inhibitors, pharmaceutical compositions, and methods related thereto EMORY UNIVERSITY (US) 2026-03-17 — — US disclosed
US-20250262566-A1 DEVICE FOR SEPARATING AN ANALYTE FROM OTHER COMPONENTS IN AN ELECTROLYTIC SOLUTION NYCTEA TECH AB (SE) 2025-08-21 — — US disclosed
US-20250249103-A1 Photolysis to Unlock Caged Protein Therapeutics UNIV EMORY (US) 2025-08-07 — — US disclosed
US-12378329-B2 Zwitterionically modified polymers and hydrogels CORNELL UNIVERSITY (US) 2025-08-05 — — US disclosed
US-20250205360-A1 FUNCTIONALIZED CORE-SHELL NANOGEL SCAVENGER FOR IMMUNE MODULATION THERAPY UNIV NEW YORK STATE RES FOUND (US) 2025-06-26 — — US disclosed
CN-110381956-A Zwitterionic modified polymers and hydrogels 康奈尔大学 2019-10-25 — — CN disclosed
CN-110029499-A Medical high polymer three-dimensional structure composite material and preparation method 苏州大学附属第二医院 2019-07-19 — — CN disclosed
CN-106334463-B A kind of anti-pollution polyvinylidene fluoride hollow-fibre membrane and preparation method thereof 东华大学 2019-02-01 — — CN disclosed
CN-107903339-A The chitosan derivatives and preparation method of a kind of group containing amphoteric amino acids and application 暨南大学 2018-04-13 — — CN disclosed
CN-106334463-A Anti-pollution polyvinylidene fluoride hollow-fiber membrane and preparation method thereof 东华大学 2017-01-18 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12378329-B2 Zwitterionically modified polymers and hydrogels CHRM1, CHRM2, F12 GRIK1 429/4885GRIK2 1291/4885GRM1 349/4885
US-12577278-B2 KRAS G12V mutant binds to JAK1, inhibitors, pharmaceutical compositions, and methods related thereto KRAS, JAK1, JAK2 GRIK1 2661/4885GRIK2 3967/4885GRM1 2276/4885
US-20250205360-A1 FUNCTIONALIZED CORE-SHELL NANOGEL SCAVENGER FOR IMMUNE MODULATION THERAPY TST, CD44, TSLP GRIK1 3753/4885GRIK2 3733/4885GRM1 3045/4885
US-20250249103-A1 Photolysis to Unlock Caged Protein Therapeutics IL2, IL6, S100A6 GRIK1 4812/4885GRIK2 4749/4885GRM1 4608/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback